Skip to search formSkip to main contentSkip to account menu

Response Evaluation Criteria in Solid Tumors

Known as: RECIST 
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
9504Background: In the phase III KEYNOTE-006 study (NCT01866319), pembro (anti–PD-1) provided superior OS and PFS and a lower… 
Highly Cited
2016
Highly Cited
2016
7 Background: PD-L1 and PD-L2 expression have been associated with poor prognosis in esophageal cancer. Pembrolizumab (pembro) is… 
Highly Cited
2014
Highly Cited
2014
5012 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) inhibitor antibody, has shown encouraging activity in… 
Highly Cited
2012
Highly Cited
2012
PurposeThis study evaluated the ability of 18F-FDG PET/CT imaging to predict early response to 90Y-radioembolization in… 
Highly Cited
2012
Highly Cited
2012
Dendritic cells (DCs) electroporated with mRNA encoding CD70, CD40L and a constitutively active toll-like receptor 4 (TriMix-DC… 
Review
2006
Review
2006
Response evaluation criteria in solid tumors (RECIST) guidelines were published in 2000 to evaluate response to treatment in… 
Highly Cited
2004
Highly Cited
2004
4500 Background: SU011248 is an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… 
2002
2002
BackgroundIn 1999 European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States and…